A Study To Learn About The Effects Of Pneumococcal Vaccine In People With HIV

Completed

Conditions studied: HIV, Pneumonia, Infections, Pneumococcal

In brief

The purpose of this study is to learn about how well a vaccine (Prevnar 13, PCV13) works in preventing disease in adults with HIV. The diseases studied are pneumonia. Mostly the ones caused by the bacteria - pneumococcus. This study also evaluates the type of pneumonia that is spread into the bloodstream. All participants in the study will be identified in health care databases. Adults with HIV will be identified by looking for a medical diagnosis that has confirmed HIV from the databases. Vaccination will be identified in the databases by looking for vaccine administration or for PCV13. Participants will be followed in the databases to see if they have one of the diseases mentioned above or not. The number of vaccinated participants with the diseases will be compared to the number participants without the vaccines but with the diseases. This will help to understand how well the vaccine worked.

Key facts

Study ID

NCT05794191

Run by

Pfizer

People needed

350399

Starts

2023-03-22

Expected to finish

2024-08-15

Last updated by the study team

2025-10-20

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• HIV infection defined as at least one inpatient or ≥2 outpatient codes related to HIV at least 30 days but no more than 730 days apart
• At least 18 years of age at the time of the first HIV-related code
• At least six months of continuous enrollment in medical and pharmacy plans after the first HIV-related code

You may not qualify if…

• Evidence of PCV13 vaccination before the first HIV-related code

Where it is running

• Pfizer — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.